Hear are the trends we spotted this week in women’s health, and as always, scroll for the top clicked stories.

• 🧬 Personalization is the theme of the moment. From a major JAMA trial showing risk-based mammogram schedules work as well as annual screening, to expanded FDA approval of a libido drug for postmenopausal women, women’s health is slowly moving away from one-size-fits-all care—at least in clinical research and regulation.

• ⚠️ Opposition matters. The Trump administration cavalierly claimed they’d simply burn a $10M birth control stockpile at the start of 2025, but this week we learned that stockpile is just sitting there. And now they’ll have to share with a court exactly why. It’s a long process, but it shows that voices in opposition matter.

• 📉 Better measurement is revealing uncomfortable truths. Objective blood-loss tools show postpartum hemorrhage is far more common than previously believed, echoing a broader pattern this year: when women’s health is actually measured accurately, the burden of disease looks much larger than we’ve been told.

Editor’s Note: This will be the last edition of the newsletter in 2025! Thank you for being a dedicated reader of the women’s health news that so often gets ignored. We will be back on January 6.

TOP CLICKED STORIES THIS WEEK

• FDA clears first libido-boosting pill for menopausal women // ABC News

• Breast cancer screening may soon be personalized by risk, not age // The New York Times

• Looking back — and ahead — at women’s health research in 2025 // Society for Women’s Health Research

• Inside the global fertility and surrogacy pipeline // The New York Times

• AAP warns funding cuts could undermine vaccine guidance // The New York Times

• Falling birth rates may help narrow the gender wage gap // Futurity